Cube Biotech and IBA Lifesciences in acquisition deal

 Cube Biotech and IBA Lifesciences join forces to advance research and production capabilities for the life science industry by leveraging its complementary strengths to deliver unparalleled solutions in protein purification and stabilization and to enable groundbreaking research in the field of challenging drug targets.

Cube Biotech’s vision to accelerate innovation, simplify services, and broaden its global presence is reflected in the acquisition. Over the course of the last 12 months, the company has formed multiple collaborations to realize these goals. By combining Cube Biotech’s expertise in protein technologies with IBA Lifesciences strength in high performance research tools for protein isolation and analysis, the new entity is uniquely positioned to address the evolving needs of researchers and industry professionals worldwide.

According to the press release, the strategic highlights of the acquisition are:

• Enhanced Product Portfolio: Integration of Cube Biotech’s portfolio of stabilized membrane proteins via its NativeMP™ platform and purification resins with IBA Lifesciences’ proprietary Strep-tag® affinity technology.
• Global Reach: Expanding distribution channels and operational capabilities to better serve customers in North America, Europe, and Asia.
• Innovative R&D Synergy: Combining research and development teams to drive groundbreaking advancements in life science research and the drug discovery value chain.
• Customer-Centric Solutions: Focus on delivering comprehensive, customizable solutions tailored to the specific needs of pharmaceutical, biotech and academic customers.

Didier Dargent, CEO of Cube Biotech, stated:“This acquisition marks an exciting new chapter for both companies. Together, we will harness our collective expertise to push the boundaries of what’s possible in the life sciences and enable researchers to make groundbreaking discoveries.”

Mike Rothe, CEO of IBA Lifesciences, said: “The fusion of our technologies and talents creates an outstanding foundation for innovation. Our combined efforts will benefit our customers and strengthen our position as leaders in the biotechnology market.”